Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 35392088)

  • 1. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
    Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
    Front Immunol; 2022; 13():831636. PubMed ID: 35392088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
    Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
    Immunobiology; 2024 May; 229(3):152802. PubMed ID: 38569452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
    Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
    Front Immunol; 2021; 12():774103. PubMed ID: 35250965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition.
    Li K; Wu L; Chen Y; Li Y; Wang Q; Li M; Hao K; Zhang W; Jiang S; Wang Z
    Drug Des Devel Ther; 2020; 14():5315-5324. PubMed ID: 33293793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling.
    Wang B; Zhang X; Li ZS; Wei C; Yu RZ; Du XZ; He YJ; Ren Y; Zhen YW; Han L
    Cancer Lett; 2024 Mar; 585():216665. PubMed ID: 38290657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.
    Zhu Y; Zhang X; Qi L; Cai Y; Yang P; Xuan G; Jiang Y
    Oncotarget; 2016 Mar; 7(12):14429-40. PubMed ID: 26894862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.
    Gao X; Jiang W; Ke Z; Huang Q; Chen L; Zhang G; Li C; Yu X
    Biochem Biophys Res Commun; 2022 Jan; 586():34-41. PubMed ID: 34826698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.
    Wang B; Cao C; Liu X; He X; Zhuang H; Wang D; Chen B
    Cell Oncol (Dordr); 2020 Apr; 43(2):223-235. PubMed ID: 31776938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
    Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
    Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.
    Tu M; Wange W; Cai L; Zhu P; Gao Z; Zheng W
    Tumour Biol; 2016 Nov; 37(11):14701-14709. PubMed ID: 27623944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic, transcriptomic, and epigenetic analyses identify a leukotriene synthesis-related M2 macrophage gene signature that predicts prognosis and treatment vulnerability in gliomas.
    Ji H; Liu Z; Wang N; Jin J; Zhang J; Dong J; Wang F; Yan X; Gong Q; Zhao H; Sun H; Li Y; Hu S; You C
    Front Immunol; 2022; 13():970702. PubMed ID: 36159811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeling cancer stemness by collagen/fibronectin
    Zhong C; Tao B; Tang F; Yang X; Peng T; You J; Xia K; Xia X; Chen L; Peng L
    Theranostics; 2021; 11(4):1991-2005. PubMed ID: 33408794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.